Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis.

Balleari E, Filiberti RA, Salvetti C, Allione B, Angelucci E, Bruzzone M, Calzamiglia T, Cavaliere M, Cavalleri M, Cilloni D, Clavio M, Crisà E, Da Col A, Danise P, Pilo F, Ferrero D, Finelli C, Gioia D, Lemoli RM, Masiera E, Messa E, Miglino M, Musto P, Natalie Oliva E, Poloni A, Salvi F, Sanna A, Scudeletti M, Tassara R, Santini V.

Cancer Med. 2019 Oct 27. doi: 10.1002/cam4.2638. [Epub ahead of print]

2.

Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study.

Messa E, Gioia D, Masiera E, Castiglione A, Ceccarelli M, Salvi F, Danise P, Sanna A, Allione B, Balleari E, Poloni A, Cametti G, Ferrero D, Tassara R, Finelli C, Bonferroni M, Musto P, Saglio G, Levis A, Santini V.

Haematologica. 2019 Jan;104(1):e4-e8. doi: 10.3324/haematol.2017.183590. Epub 2018 Aug 3. No abstract available.

3.

Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study.

Messa E, Biale L, Castiglione A, Lunghi M, Bonferroni M, Salvi F, Allione B, Ferrero D, Calabrese C, De Gobbi M, Nicoli P, Gioia D, Levis A, Saglio G, Cilloni D.

Leuk Lymphoma. 2017 Nov;58(11):2752-2754. doi: 10.1080/10428194.2017.1312385. Epub 2017 May 9. No abstract available.

4.

Core binding factor acute myeloid leukaemia and c-KIT mutations.

Riera L, Marmont F, Toppino D, Frairia C, Sismondi F, Audisio E, Di Bello C, D'Ardia S, Di Celle PF, Messa E, Inghirami G, Vitolo U, Pich A.

Oncol Rep. 2013 May;29(5):1867-72. doi: 10.3892/or.2013.2328. Epub 2013 Mar 5.

5.

Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study.

Galimberti S, Guerrini F, Salvi F, Petrini I, Gioia D, Messa E, Palumbo GA, Cilloni D, Petrini M, Levis A.

J Hematol Oncol. 2012 Sep 10;5:53. doi: 10.1186/1756-8722-5-53.

6.

Iron chelation therapy in myelodysplastic syndromes.

Messa E, Cilloni D, Saglio G.

Adv Hematol. 2010;2010:756289. doi: 10.1155/2010/756289. Epub 2010 Jun 20.

7.

Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging.

Messa E, Carturan S, Maffè C, Pautasso M, Bracco E, Roetto A, Messa F, Arruga F, Defilippi I, Rosso V, Zanone C, Rotolo A, Greco E, Pellegrino RM, Alberti D, Saglio G, Cilloni D.

Haematologica. 2010 Aug;95(8):1308-16. doi: 10.3324/haematol.2009.016824. Epub 2010 Jun 9.

8.

Emerging drugs for chronic myeloid leukemia.

Cilloni D, Messa E, Rotolo A, Saglio G.

Expert Opin Emerg Drugs. 2010 Jun;15(2):175-84. doi: 10.1517/14728211003621220. Review.

PMID:
20201747
9.

WITHDRAWN: Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity.

Cilloni D, Carturan S, Maffè C, Messa F, Arruga F, Messa E, Pradotto M, Pautasso M, Zanone C, Fornaciari P, Defilippi I, Rotolo A, Greco E, Iacobucci I, Martinelli G, Lo-Coco F, Bracco E, Saglio G.

Leukemia. 2010 Jan 14. [Epub ahead of print]

PMID:
20072158
10.

Identification of a novel mutation in the L ferritin iron-responsive element causing hereditary hyperferritinemia-cataract syndrome.

Messa E, Pellegrino RM, Palmieri A, Carturan S, Cilloni D, Saglio G, Roetto A.

Acta Haematol. 2009;122(4):223-5. doi: 10.1159/000253031. Epub 2009 Oct 29. No abstract available.

PMID:
19887780
11.

Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.

Messa E, Cilloni D, Messa F, Arruga F, Roetto A, Saglio G.

Acta Haematol. 2008;120(2):70-4. doi: 10.1159/000158631. Epub 2008 Oct 1.

PMID:
18827475
12.

Detection of humoral immune responses against WT1 antigen in patients affected by different hematological malignancies.

Nicoli P, Defilippi I, Carturan S, Roetto A, Messa F, Arruga F, Messa E, Rotolo A, Iacobucci I, Bracco E, Saglio G, Cilloni D.

Acta Haematol. 2008;120(1):47-50. doi: 10.1159/000158576. Epub 2008 Sep 30. No abstract available.

PMID:
18824841
13.

Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy.

Cilloni D, Messa F, Arruga F, Defilippi I, Gottardi E, Fava M, Carturan S, Catalano R, Bracco E, Messa E, Nicoli P, Diverio D, Sanz MA, Martinelli G, Lo-Coco F, Saglio G.

Haematologica. 2008 Jun;93(6):921-4. doi: 10.3324/haematol.12165. Epub 2008 Apr 28.

14.

Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.

Cilloni D, Messa F, Rosso V, Arruga F, Defilippi I, Carturan S, Catalano R, Pautasso M, Panuzzo C, Nicoli P, Messa E, Morotti A, Iacobucci I, Martinelli G, Bracco E, Saglio G.

Leukemia. 2008 Jun;22(6):1234-40. doi: 10.1038/leu.2008.68. Epub 2008 Apr 10. Retraction in: Leukemia. 2010 May;24(5):1103.

PMID:
18401421
15.

Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study.

Piccaluga PP, Malagola M, Rondoni M, Arpinati M, Paolini S, Candoni A, Fanin R, Messa E, Pirrotta MT, Lauria F, Visani G, Alberti D, Rancati F, Vinaccia V, Russo D, Saglio G, Baccarani M, Martinelli G.

Haematologica. 2007 Dec;92(12):1721-2.

16.

A young man with persistent eosinophilia.

Messa E, Cilloni D, Saglio G.

Intern Emerg Med. 2007 Jun;2(2):107-12. No abstract available.

PMID:
17622494
17.

WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia.

Cilloni D, Messa F, Martinelli G, Gottardi E, Arruga F, Defilippi I, Carturan S, Messa E, Fava M, Giugliano E, Rosso V, Catalano R, Merante S, Nicoli P, Rondoni M, Ottaviani E, Soverini S, Tiribelli M, Pane F, Baccarani M, Saglio G.

Leukemia. 2007 Jul;21(7):1442-50. Epub 2007 May 17.

PMID:
17508006
18.

Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.

Cilloni D, Messa E, Messa F, Carturan S, Defilippi I, Arruga F, Rosso V, Catalano R, Bracco E, Nicoli P, Saglio G.

Ann N Y Acad Sci. 2006 Nov;1089:411-23. Review.

PMID:
17261784
19.

The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance.

Cilloni D, Messa F, Arruga F, Defilippi I, Morotti A, Messa E, Carturan S, Giugliano E, Pautasso M, Bracco E, Rosso V, Sen A, Martinelli G, Baccarani M, Saglio G.

Leukemia. 2006 Jan;20(1):61-7.

PMID:
16270044
20.

Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.

Pilatrino C, Cilloni D, Messa E, Morotti A, Giugliano E, Pautasso M, Familiari U, Cappia S, Pelicci PG, Lo Coco F, Saglio G, Guerrasio A.

Cancer. 2005 Jul 1;104(1):101-9.

21.

Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia.

Saglio G, Morotti A, Mattioli G, Messa E, Giugliano E, Volpe G, Rege-Cambrin G, Cilloni D.

Ann N Y Acad Sci. 2004 Dec;1028:423-31. Review.

PMID:
15650267
22.

Myelodysplastic syndromes.

Cilloni D, Messa F, Carturan S, Arruga F, Defilippi I, Messa E, Gottardi E, Saglio G.

Ann N Y Acad Sci. 2004 Dec;1028:400-8. Review.

PMID:
15650265
23.

Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.

Cilloni D, Messa F, Gottardi E, Fava M, Arruga F, Defilippi I, Carturan S, Messa E, Morotti A, Giugliano E, Rege-Cambrin G, Alberti D, Baccarani M, Saglio G.

Cancer. 2004 Sep 1;101(5):979-88.

24.

Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia.

Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, Amabile M, Soverini S, Castagnetti F, Cilloni D, Izzo B, de Vivo A, Messa E, Bonifazi F, Poerio A, Luatti S, Giugliano E, Alberti D, Fincato G, Russo D, Pane F, Saglio G; GIMEMA Working Party on Chronic Myeloid Leukemia.

Blood. 2004 Dec 15;104(13):4245-51. Epub 2004 Aug 19.

PMID:
15319292
25.

Down-modulation of the C/EBPalpha transcription factor in core binding factor acute myeloid leukemias.

Cilloni D, Carturan S, Gottardi E, Messa F, Messa E, Fava M, Diverio D, Guerrasio A, Lo-Coco F, Saglio G.

Blood. 2003 Oct 1;102(7):2705-6. No abstract available.

PMID:
14504076
26.

[Lymph node myofibroblastoma: report of a submandibular case with peculiar morphologic and immunohistochemical characteristics].

Ambrosiani L, Bellone S, Cecchetti G, Ceretti E, Messa E, Tavani E.

Pathologica. 1994 Oct;86(5):541-5. Italian.

PMID:
7739882
27.

Cerebellar syndrome in lithium poisoning: a case of partial recovery.

Tesio L, Porta GL, Messa E.

J Neurol Neurosurg Psychiatry. 1987 Feb;50(2):235. No abstract available.

Supplemental Content

Support Center